{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:20:12Z","timestamp":1771050012593,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hilton Pharmaceutical company","award":["NIBD\/2019\/1010"],"award-info":[{"award-number":["NIBD\/2019\/1010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Convalescent plasma(CP)\u00a0was utilized as potential therapy during COVID-19 pandemic in Pakistan. The study aimed at appraisal of CP transfusion safety and usefulness in COVID pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Single arm, MEURI study design of non-randomized open label trial was conducted in five centers. Patients\u00a0werecategorized as moderately severe, severe, and critical. The\u00a0primary endpoint\u00a0was a) improvement in clinical status and change in category of disease severity; secondary endpoint\u00a0was b) CP ability to halt disease progression to invasive ventilation. CP transfused to hospitalized patients. Statistical tests including median (interquartile ranges), Mann-Whitney U test, Fisher\u2019s exact test using SPSS ver. 23, ANOVA and Chi-square test were applied for the analysis of results parameters before and after CP treatment. SOFA score\u00a0was applied for multiorgan failure in severe and critical cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 50 adult patients; median age 58.5\u2009years (range: 29\u201392\u2009years) received CP with infusion titers; median 1:320\u2009U\/mL (Interquartile range 1:80\u20131:320) between April 4 to May 5, 2020. The median time from onset of symptoms to enrollment in trial was 3 to 7\u2009days with\u00a0shortness of breath\u00a0and lung infiltration as severity criterion. In 35 (70%) recipients, oxygen saturation improved from 80 to 95% within 72h, with resolution of lung infiltrates. Primary endpoint was\u00a0achieved in 44 (88%) recipients whereas secondary endpoint\u00a0was achieved in 42 (84%). No patient experienced severe adverse events. A high SOFA score (<jats:underline>&gt;<\/jats:underline>\u20097) correlated with deaths in severe and critical patients. Eight (16%) patients expired due to comorbidities; cardiac arrest in 2 (4%), multiorgan failure secondary to cytokine storm in 5 (10%) and ventilator associated complications in 1 (2%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CP transfusion can be used as a safe and useful treatment in moderately severe and severe patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial registration number is <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04352751\">NCT04352751<\/jats:ext-link>\u00a0(<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.irct.ir\/search\/result?query=IRCT20200414047072N1\">https:\/\/www.irct.ir\/search\/result?query=IRCT20200414047072N1<\/jats:ext-link>). Trial Registration date is 28th April 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06451-7","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T15:03:17Z","timestamp":1632754997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-7375","authenticated-orcid":false,"given":"Tehmina Nafees Sonia","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samina Naz","family":"Mukry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahtaj","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Meraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bikha Ram","family":"Devrajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveena","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidra","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Mahesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roomana","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadia","family":"Ishaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Bilal","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanam","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshi","family":"Naz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahir Sultan","family":"Shamsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"6451_CR1","doi-asserted-by":"crossref","unstructured":"Siddell SG. The coronaviridae. Springer.\u00a01995:1\u201310.\u00a0https:\/\/www.springer.com\/gp\/book\/9780306449727.","DOI":"10.1007\/978-1-4899-1531-3_1"},{"issue":"10224","key":"6451_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8.","journal-title":"Lancet"},{"key":"6451_CR3","doi-asserted-by":"publisher","unstructured":"Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ. 2020;728:138861. https:\/\/doi.org\/10.1016\/j.scitotenv.2020.138861. Epub 2020 Apr 22.","DOI":"10.1016\/j.scitotenv.2020.138861"},{"issue":"1","key":"6451_CR4","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","volume":"81","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21\u2013e3. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.060.","journal-title":"J Infect"},{"issue":"10","key":"6451_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cmi.2020.08.005","volume":"26","author":"DJ Wooding","year":"2020","unstructured":"Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436\u201346. https:\/\/doi.org\/10.1016\/j.cmi.2020.08.005.","journal-title":"Clin Microbiol Infect"},{"key":"6451_CR6","doi-asserted-by":"publisher","first-page":"m1256","DOI":"10.1136\/bmj.m1256","volume":"368","author":"JH Tanne","year":"2020","unstructured":"Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256.","journal-title":"BMJ."},{"key":"6451_CR7","doi-asserted-by":"crossref","unstructured":"Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. Infection, Disease & Health,\u00a02020;25(3):210\u20135.","DOI":"10.1016\/j.idh.2020.05.002"},{"key":"6451_CR8","doi-asserted-by":"crossref","unstructured":"Rojas M, Rodr\u00edguez Y, Monsalve D, Acosta-Ampudia Y, Camacho B, Gallo J et al. Convalescent plasma in Covid-19: Possible mechanisms of action.\u00a0Autoimmun. Rev.\u00a02020;19(7):102554.","DOI":"10.1016\/j.autrev.2020.102554"},{"issue":"7","key":"6451_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"J-H Ko","year":"2018","unstructured":"Ko J-H, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617\u201322. https:\/\/doi.org\/10.3851\/IMP3243.","journal-title":"Antivir Ther"},{"issue":"17","key":"6451_CR10","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020;117(17):9490\u20136. https:\/\/doi.org\/10.1073\/pnas.2004168117.","journal-title":"Proc Natl Acad Sci"},{"key":"6451_CR11","doi-asserted-by":"publisher","unstructured":"Siracusano G, Pastori C, Lopalco L. Humoral immune responses in COVID-19 patients: a window on the state of the art. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.01049.","DOI":"10.3389\/fimmu.2020.01049"},{"key":"6451_CR12","doi-asserted-by":"crossref","unstructured":"Erika P, Domenica Z, Paolo I, Luca R, Giulia L, Alessandro D, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clinca Chimica Acta. 2020;509:135\u20138.","DOI":"10.1016\/j.cca.2020.06.012"},{"key":"6451_CR13","doi-asserted-by":"crossref","unstructured":"Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020.","DOI":"10.1101\/2020.03.26.20040709"},{"key":"6451_CR14","unstructured":"Perumallapalli AK, Prasad S, Singh D, Priyadarshini A, Naidu SA. Use of Convalescent Plasma in COVID-19. PUMRJ [Internet]. 1 Aug. 2020;3(SPECIAL). Available from:https:\/\/www.praxisug.com\/index.php\/Praxis\/article\/view\/92."},{"key":"6451_CR15","doi-asserted-by":"publisher","first-page":"104358","DOI":"10.1016\/j.jcv.2020.104358","volume":"127","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol. 2020;127:104358. https:\/\/doi.org\/10.1016\/j.jcv.2020.104358.","journal-title":"J Clin Virol"},{"issue":"11","key":"6451_CR16","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","volume":"201","author":"Y Feng","year":"2020","unstructured":"Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380\u20138. https:\/\/doi.org\/10.1164\/rccm.202002-0445OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"6451_CR17","unstructured":"Organization W. Clinical management of COVID-19: interim guidance, 27 May 2020 [Internet]. Apps.who.int. 2021. [cited 10 January 2021]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/332196."},{"issue":"2","key":"6451_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2015432.","journal-title":"N Engl J Med"},{"key":"6451_CR19","doi-asserted-by":"crossref","unstructured":"Cavezzi A, Troiani E, Corrao S. COVID-19: Hemoglobin, Iron, and Hypoxia beyond Inflammation. A Narrative Review. Clinics and Practice. 2020;10(2):24\u201330.","DOI":"10.4081\/cp.2020.1271"},{"key":"6451_CR20","doi-asserted-by":"crossref","unstructured":"Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F et al. Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study. Nature Medicine. 2020;26(11):1708\u201313.","DOI":"10.1038\/s41591-020-1088-9"},{"issue":"10289","key":"6451_CR21","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(21)01064-3","volume":"397","author":"ST Liu","year":"2021","unstructured":"Liu ST, Aberg JA. Convalescent plasma in patients hospitalised with COVID-19. Lancet. 2021;397(10289):2024\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(21)01064-3.","journal-title":"Lancet"},{"issue":"10","key":"6451_CR22","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/all.14456","volume":"75","author":"M Lommatzsch","year":"2020","unstructured":"Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020;75(10):2705\u20138. https:\/\/doi.org\/10.1111\/all.14456.","journal-title":"Allergy."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06451-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06451-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T13:03:35Z","timestamp":1655903015000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06451-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6451"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06451-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the National Bioethics Committee and institutional ethics committee at NIBD and participants have given written consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1014"}}